New T cell therapy for patients with relapsed Non-Hodgkin Lymphoma
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
['FUNDING_SBIR_2'] · MARKER THERAPEUTICS, INC. · NIH-10922163
This study is testing a new treatment for people with relapsed Non-Hodgkin Lymphoma that uses their own immune cells to better fight cancer by targeting multiple markers on the cancer cells, with the hope of making the treatment more effective and lowering the risk of the cancer coming back.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MARKER THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10922163 on ClinicalTrials.gov |
What this research studies
This research investigates a novel treatment using patient-derived T cells that target multiple tumor-associated antigens in individuals with relapsed Non-Hodgkin Lymphoma (NHL). The approach involves collecting a patient's own immune cells through a process called apheresis, which are then modified to recognize and attack cancer cells expressing specific antigens. By targeting multiple antigens simultaneously, this therapy aims to improve the effectiveness of treatment and reduce the chances of cancer relapse. Patients will be closely monitored for safety and effectiveness throughout the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with relapsed Non-Hodgkin Lymphoma who have previously undergone CAR T cell therapy and are seeking new treatment options.
Not a fit: Patients with Non-Hodgkin Lymphoma who have not relapsed or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with relapsed Non-Hodgkin Lymphoma who currently have limited alternatives.
How similar studies have performed: While CAR T cell therapies have shown success in treating NHL, this approach of targeting multiple tumor-associated antigens is relatively novel and has not been widely tested.
Where this research is happening
HOUSTON, UNITED STATES
- MARKER THERAPEUTICS, INC. — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VERA, JUAN FERNANDO — MARKER THERAPEUTICS, INC.
- Study coordinator: VERA, JUAN FERNANDO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.